---

---

publishing date : 2022 - 05 - 03    tags : Treatment   

save search

---

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie's Disease
Published: 2022-05-03 (Crawled : 00:00) - biospace.com/
PTPI | $0.8041 -3.57% -3.71% 540K |

| -24.87% | O: 7.21% H: 0.0% C: 0.0%
treatment disease

---

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
Published: 2022-05-03 (Crawled : 22:00) - globenewswire.com
PHAT | $10.01 -1.28% -1.3% 580K |

Health Technology

| -30.69% | O: -3.35% H: 0.0% C: -3.47%
treatment fda approval infection infections

---

LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
LIAN | $4.92 0.41% 0.41% 410K |

Professional, Scientific, and T...

| 31.81% | O: -2.43% H: 5.25% C: -12.98%
TARS | $35.02 -3.18% -3.28% 330K |

Health Technology

| 158.36% | O: -0.79% H: 0.36% C: -6.05%
tp-03 treatment topline trial positive

---

Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
XENE | $41.37 0.17% 0.17% 360K |

Health Technology

| 42.17% | O: -0.22% H: 0.0% C: 0.0%
xen1101 treatment trial phase 2 major depressive disorder

---

Curative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Formulations for Treatment of Macular Degeneration
Published: 2022-05-03 (Crawled : 15:20) - prnewswire.com
CUBT | $0.023 -42.11% 340K |

n/a

| -42.36% | O: -2.26% H: 2.05% C: 0.0%
treatment drop macular eye

---

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-05-03 (Crawled : 13:20) - biospace.com/
PLRX | $13.55 -4.24% -4.43% 270K |

Health Technology

| 150.44% | O: 0.88% H: 2.62% C: -5.26%
pln-7480 treatment fda fibrosis designation therapeutics fast track designation

---

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
Published: 2022-05-03 (Crawled : 13:00) - biospace.com/
TSHA | $2.66 -9.52% -10.53% 2M |

Health Technology

| -22.63% | O: 5.0% H: 9.02% C: 7.52%
tsha-120 treatment designation drug

---

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
GRPH 4 | $3.27 1.84% 490K |

Professional, Scientific, and T...

| -21.67% | O: -1.97% H: 5.28% C: 5.03%
gph101 treatment fda designation disease granted fast track designation

---

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
BTAI 4 | $2.73 -5.86% -6.23% 480K |

Health Technology

| -78.19% | O: 4.1% H: 1.65% C: 1.01%
treatment disease trial therapeutics alzheimer’s phase 3 alzheimer's

---

Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
BHC | $8.63 -1.48% 0.0% 3.2M |

Health Technology

| -53.21% | O: 0.43% H: 1.3% C: -0.74%
nov03 treatment research trial phase 3

---

Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
RVPH | $3.4 -7.86% -8.53% 730K |

| 91.19% | O: -8.29% H: 14.69% C: 10.17%
treatment brilaroxazine schizophrenia phase 3

---

Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 08:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M |

Health Technology

| -7.73% | O: 0.41% H: 0.0% C: 0.0%
cabometyx treatment cancer

---

Gainers vs Losers

49%

51%

Top 10 Gainers

KAVL | $6.275 135.02% 57.45% 44M |

Wholesale Trade

PXMD | $0.7375 79.09% 44.16% 4.5M |

Health Technology

DYNT | $0.371 -5.12% 43.09% 3.3M |

Health Technology

LGVN P 3 d | $2.94 73.96% 42.52% 57M |

HUBC | $1.94 49.23% 32.99% 73M |

n/a

SPCB | $0.4044 46.52% 31.75% 130M |

Electronic Technology

ONVO | $1.34 32.66% 24.62% 54M |

Health Technology

OMQS | $0.6869 32.1% 24.3% 3.6M |

Professional, Scientific, and T...

SNPO | $10.555 29.67% 22.88% 4M |

AMBI | $3.72 -26.77% 21.77% 9.8K |

n/a

---

Your saved searches

---